[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Yan Huang(Chinese PLA General Hospital), Li Zhang(Gdańsk Medical University), Gang Wu(Hubei University of Chinese Medicine), Zhihuang Hu, Shun-Jin Wang(Nanchang University), Jian Fang(Peking University), Xiaoqing Liu(Academy of Military Medical Sciences), Wenchao Liu(University of Chicago), Kai Li(University of Michigan), Yajie Wang(Second Military Medical University), You Lü(Sichuan University), Wei Liu(Hebei Medical University), Yiping Zhang(Zhejiang Cancer Hospital), Shiying Yu(Dalian Ocean University), Houjie Liang(Army Medical University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Baolan Li(Capital Medical University), Nong Xu(Zhejiang University), Cheng Huang(Army Medical University), Yunpeng Liu(Shenyang Institute of Automation), Zhehai Wang(Shandong Tumor Hospital), Jianhua Chang(Shanghai Medical College of Fudan University), Jianying Zhou(First Affiliated Hospital Zhejiang University)
Cited by 5
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k